Dummer, R., Daud, A., Puzanov, I., Hamid, O., Schadendorf, D., Robert, C., … Ribas, A. (2015). A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (Accepted). Journal of Translational Medicine, 1–2. https://doi.org/10.1186/1479-5876-13-S1-O5

Dummer, R., A. Daud, I. Puzanov, O. Hamid, D. Schadendorf, C. Robert, J. Schachter, et al. “A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (Accepted).” Journal of Translational Medicine, January 15, 2015, 1–2. https://doi.org/10.1186/1479-5876-13-S1-O5.

Dummer R, Daud A, Puzanov I, Hamid O, Schadendorf D, Robert C, et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (Accepted). Journal of Translational Medicine. 2015 Jan 15;1–2.

Dummer, R., et al. “A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (Accepted).” Journal of Translational Medicine, Jan. 2015, pp. 1–2. Scopus, doi:10.1186/1479-5876-13-S1-O5.

Dummer R, Daud A, Puzanov I, Hamid O, Schadendorf D, Robert C, Schachter J, Pavlick A, Gonzalez R, Hodi FS, Cranmer LD, Blank C, O’Day SJ, Ascierto PA, Salama AKS, Li NX, Zhou W, Lis J, Ebbinghaus S, Kang PS, Ribas A. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (Accepted). Journal of Translational Medicine. 2015 Jan 15;1–2.